Print Issue: December 01, 2010

Two-Drug Combination May Improve Lipid Goals

New results suggest that combination therapy with ezetimibe/simvastatin, when prescribed at the recommended starting and next higher doses, is more likely to improve lipids than atorvastatin alone in patients with metabolic syndrome.

Dutasteride May Decrease PCa Diagnosis Risk

Dutasteride (Avodart) treatment significantly reduces the relative risk of a prostate cancer (PCa) diagnosis in men with benign prostatic hyperplasia (BPH) undergoing screening with PSA tests and digital rectal examinations (DREs), new findings suggest.

Next post in News